Introduction
============

The development of lytic bone lesions due to multiple myeloma bone disease (MMBD) is a hallmark of multiple myeloma (MM).^[@b1-1031359]^ MMBD occurs in more than 80% of MM patients^[@b2-1031359]^ and is caused by an uncoupling of bone remodeling. MMBD not only results in morbidity but also directly stimulates MM tumor growth through multiple mechanisms, resulting in a vicious cycle of bone destruction and MM growth.^[@b3-1031359],[@b4-1031359]^ Although novel therapies continue to increase the life expectancy for MM patients, lytic bone lesions in these patients rarely heal.^[@b4-1031359]^ Bisphosphonates are the current standard of care for MMBD but can be responsible for side effects such as osteonecrosis of the jaw, renal impairment, atypical fractures and hypocalcemia.^[@b5-1031359],[@b6-1031359]^ These limitations highlight the need for new therapeutic strategies that ideally have a combined anti-MM and anti-MMBD effect.

We recently reported that maternal embryonic leucine zipper kinase (MELK) expression is strongly associated with proliferative high-risk MM, and that MELK inhibition with a small molecule inhibitor, OTSSP167, reduces tumor load in a murine MM model.^[@b7-1031359]^ Overexpression of MELK as well as an inverse correlation between MELK expression and survival has been reported for multiple malignancies.^[@b8-1031359]--[@b10-1031359]^ MELK promotes cell cycle progression and interacts with M-phase inducer phosphatase 2 (CDC25B) and co-localizes with key cell cycle regulators such as cyclin B1 and cyclin-dependent kinase 1 (CDK1).^[@b11-1031359]^ Downstream targets of MELK include the transcription factor forkhead box protein M1 (FOXM1)^[@b12-1031359]^ and the histone-methyltransferase enhancer of zeste homolog 2 (EZH2).^[@b13-1031359]^ Of note, FOXM1 can also directly regulate MELK expression,^[@b10-1031359]^ presumably resulting in a positive feedback loop, and has been identified as a therapeutic target for high-risk MM.^[@b14-1031359]^

The role of MELK and FOXM1 in osteoclasts and osteoblasts has not yet been explored. Regarding EZH2, Fang *et al*. showed that EZH2 promotes osteoclastogenesis by reducing the transcription factor IRF8 and subsequent upregulation of NFATC1.^[@b15-1031359]^ In addition, EZH2 prevents osteogenic differentiation of mesenchymal cells and suppression of runt-related transcription factor 2 (RUNX2) has been implicated in this process.^[@b16-1031359]^ Inhibition of EZH2 has been shown to mitigate bone loss in ovariectomized mice^[@b17-1031359]^ and to reverse MM-induced suppression of osteoblast differentiation *in vitro*.^[@b18-1031359]^

Because the described roles of downstream targets of MELK suggest that its inhibition could concurrently block osteoclast function and stimulate osteoblast function, we examined the potential of OTSSP167 as a novel therapeutic agent for MMBD.

Methods
=======

Reagents
--------

OTSSP167 (Biorbyt) was dissolved in DMSO and stored at −20°C. For *in vivo* studies, OTSSP167 was dissolved in 0.5% methylcellulose (Sigma-Aldrich) and stored at −20°C. The following antibodies were used: anti-FOXM1 (SC-502, Santa Cruz), anti-EZH2 (\#4905, Cell Signaling Technology) anti-MELK (GTX111958, GeneTex and 2274S, Cell Signaling Technology), anti-α-tubulin (T6074, Sigma), anti-GAPDH (2118, Cell Signaling Technology), anti-rabbit-HRP (P0217, Agilent) and anti-mouse HRP (P0260, Agilent).

Cells and culture conditions
----------------------------

Human peripheral blood mononuclear cells (PBMCs) were obtained after Ficoll (GE Healthcare) separation of whole blood. RAW264.7 cells and 5TGM.1GFP^+^ cells were cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum (FBS)(Sigma-Aldrich), 2mM L-glutamine (Lonza) and 1% penicillin/streptomycin (P/S) (Lonza). TERT^+^ bone marrow mesenchymal stromal cells (BMSC-TERT) (kindly provided by Dr. D Campana, St. Jude Children's Research Hospital, Memphis, TN, USA) were cultured in RPMI-1640 (Gibco) supplemented with 10% FCS, 2mM L-glutamine and 1% P/S.

Cell viability assay and cell cycle analysis
--------------------------------------------

RAW264.7 and PBMC viability were assessed with the cell proliferation kit I (Roche). BMSC-TERT viability was assessed with the Cell Counting Kit 8 (Sigma-Aldrich). For cell cycle analysis, cells were stained using PI/RNase staining buffer (BD Biosciences), followed by FACS analysis on a FACSCalibur (BD Biosciences).

Osteoclast differentiation and *in vitro* bone matrix resorption
----------------------------------------------------------------

PBMCs were seeded at a density of 750,000 cells/cm^2^ in alpha-MEM (Lonza) supplemented with 10% FCS, 2 mM L-glutamine and 1% P/S. Cells were left to adhere for 4 hours. Next, the medium was refreshed and supplemented with 25 ng/ml human M-CSF and 50 ng/ml human sRANKL (Peprotech). The culture medium was refreshed twice per week and cultures were stopped on day 14. RAW264.7-derived osteoclast cultures were established as described previously.^[@b19-1031359]^ TRAP activity in osteoclast cultures was detected using the Leukocyte TRAP kit (Sigma-Aldrich). Alternatively, cultures were lysed for RNA or protein extraction. Bone resorption by osteoclasts was assessed in Osteo Assay 96-well plates (Corning) as described previously.^[@b19-1031359]^ Actin ring formation was assessed by staining cultures with phalloidin-FITC (Sigma-Aldrich), followed by analysis on an A1R confocal fluorescent microscope (Nikon).

Quantification of reactive oxygen species
-----------------------------------------

Reactive oxygen species (ROS) were detected using the Cellular Reactive Oxygen Species Detection Assay kit (Abcam). In short, cells were stained with DCDFA for 30 minutes at 37 °C and fluorescence was measured (Ex/Em = 485/535 nm) on an Infinite M200 Pro plate reader (Tecan).

Osteoblast differentiation and functional analyses
--------------------------------------------------

BMSC-TERT were seeded at a density of 25,000 cells/cm^2^ and grown to 70--80 % confluence. Osteoblast differentiation was initiated by changing the medium to alpha-MEM supplemented with 10 % FCS, 2 mM L-glutamine, 1% P/S, 100 nM dexamethasone, 50 μg/ml ascorbic acid and 3 mM β-glycerophosphate (Sigma-Aldrich). Osteogenic medium was refreshed twice per week. Collagen secretion and matrix mineralization were assessed by Sirius Red and Alizarin Red staining, respectively, as described previously.^[@b19-1031359],[@b20-1031359]^

Real-time PCR
-------------

Real-time PCR was performed as described previously^[@b19-1031359]^ using 250 nmol/L of the appropriate primers (IDT, *Online Supplementary Table S1*) or pre-designed Taqman gene expression assays (Applied Biosystems). Gene expression was normalized to β-actin and β2-microglobubulin expression (osteoclasts) or *RPLP0* (osteoblasts). Measurements were performed at least in triplicate and relative expression levels were determined using the ΔCt method.

Western blotting
----------------

Cells were lysed in RIPA Lysis and Extraction buffer (Thermo Scientific) supplemented with cOmplete Protease Inhibitor Cocktail (Roche). Twenty μg of protein were separated by gel electrophoresis on a 10% SDS-polyacrylamide gel and transferred onto PVDF membranes (BioRad). Membranes were blocked with 5% BSA/PBS/Tween20 and incubated overnight at 4°C with primary antibodies (MELK: 1:1000, FOXM1: 1:100, EZH2: 1:1000, α-tubulin: 1:5000, GAPDH: 1:2000). The next day, blots were incubated with a HRP-conjugated secondary antibody (1:5000), followed by visualization on an ImageQuant LAS4000 (GE Healthcare).

Treatment of myeloma-bearing mice with OTSSP167
-----------------------------------------------

We used the C57BL/KaLwRij 5TGM.1 mouse model^[@b21-1031359]^ to assess the effect of OTSSP167 on the development of MMBD. Nine-week-old female mice were injected i.v. with 5.0 × 10^5^ 5TGM.1GFP+ cells and OTSSP167 or vehicle solution was administered by oral gavage at different dose levels. For every cohort, mice were randomly divided into a naive group (no MM, n=5), a vehicle group (MM + vehicle, n=10) and a treated group (MM + OTSSP167, n=10). When mice showed signs of active myeloma, i.e., paraplegia, all mice within a cohort were sacrificed. Bone marrow plasmocytosis was determined by flushing the bones of one leg followed by flow cytometry on a FACSCanto flow cytometer (BD Biosciences). The femur and tibia of the opposite leg were defleshed and stored in 70% EtOH. Ethical approval was obtained for all mouse experiments (ULg license no. 1336).

Micro-computed tomography
-------------------------

Micro-computed tomography (μCT) was performed on distal femurs with the Skyscan 1172 system (Bruker), as described previously.^[@b19-1031359]^ 3D models of bones were generated using CTVol software (Bruker). The number of cortical perforations \> 50 μm in diameter was counted blinded on reconstructed images.

Bone histomorphometry
---------------------

Femurs were embedded in methylmethacrylate. All parameters were recorded as recommended by the American Society for Bone and Mineral Research Histomorphometry Nomenclature Committee.^[@b22-1031359]^ Osteoblast surface and osteoid surface were measured on sections stained with toluidine blue and Masson's trichrome (Sigma-Aldrich). Osteoclasts were detected by TRAP staining (Sigma-Aldrich) and osteoclast surface was determined. Briefly, sections were stained for acid phosphatase using naphthol ASTR phosphate as substrate in the presence of 50 mM tartrate with hexazotised pararosaniline, and counterstained with methyl green. Measurements were performed in NDP. View 2.6.13.

Statistical analyses
--------------------

All experiments were performed at least in triplicate. Results are shown as means +/− standard error and representative images are shown. For comparisons of 2 means, a Student *t*-test was used. For comparisons of multiple means, a one-way ANOVA was used, followed by a Dunnett's post-hoc test or Tukey's post-hoc test. All statistical analyses were performed with Prism 5 (Graphpad software). *P*-values below 0.05 were considered significant and *P*-values are represented as follows: \*=*P*\<0.05, \*\*=*P*\<0.01, \*\*\*=*P*\<0.001.

Results
=======

OTSSP167 hampers osteoclast differentiation
-------------------------------------------

During normal osteoclastogenesis, MELK levels increased in osteoclasts cultured from murine RAW264.7 cells ([Figure 1A](#f1-1031359){ref-type="fig"}) or from primary human mononuclear cells (*results not shown*) when compared to monocyte cultures ([Figure 1A](#f1-1031359){ref-type="fig"}). We could confirm the earlier described^[@b15-1031359]^ osteoclast activation pathway (EZH2-IRF8-NFATC1) by showing significant increases in *EZH2, NFATC1, TRAP* and *CTSK* and a decrease in *IRF8* mRNA ([Figure 1A](#f1-1031359){ref-type="fig"}). We subsequently studied the effects of the MELK inhibitor OTSSP167 on the proliferation of osteoclast progenitor cells and on the differentiation into osteoclasts. Treatment of RAW264.7 cells with 25 nM OTSSP167 for 24 hours resulted in decreased MELK protein levels ([Figure 1B](#f1-1031359){ref-type="fig"}). Because of the described role of MELK in cell cycle progression, we assessed the effect of continuous OTSSP167 treatment on RAW264.7 and human PBMC viability, and found that the viability of both osteoclast progenitor populations decreased (IC50: 12.8 nM and 43.2 nM, respectively) ([Figure 1C](#f1-1031359){ref-type="fig"}). This coincided with an induction of G2/M cell cycle arrest (*Online Supplementary Figure S1A*). The decrease in progenitor viability corresponded with a decrease in both human ([Figure 1D](#f1-1031359){ref-type="fig"} and [1F](#f1-1031359){ref-type="fig"}) and murine ([Figure 1E](#f1-1031359){ref-type="fig"} and [1H](#f1-1031359){ref-type="fig"}) osteoclast differentiation following continuous OTSSP167 treatment. Although the number of osteoclasts decreased, osteoclast size was markedly increased in human cultures treated with 10 nM OTSSP167, with a corresponding increase in the number of nuclei per osteoclasts ([Figure 1G](#f1-1031359){ref-type="fig"}). This was not the case for RAW264.7 osteoclast cultures ([Figure 1I](#f1-1031359){ref-type="fig"}).

![OTSSP167 hampers osteoclast differentiation. A) mRNA levels of *MELK, EZH2, FOXM1* and relevant transcription factors during osteoclastogenesis in murine cultures, MO: monocytes; OC: osteoclasts. B) The effect of OTSSP167 treatment on MELK protein expression in RAW264.7 cultures. C) MTT assay on PBMCs and RAW264.7 cells incubated with a range of OTSSP167 concentrations. D+E) Representative images of TRAP-stained human (huOC) and RAW264.7-derived osteoclast cultures continuously treated with a range of OTSSP167 concentrations. F) Quantification of osteoclast numbers per field of view (N.OC/FOV) in huOC cultures. G) Number of nuclei per osteoclast in huOC cultures. H) Quantification of N.OC/FOV in RAW264.7-derived cultures. I) Number of nuclei per osteoclast in RAW264.7-derived cultures. All data are represented as mean +/− standard error. \*: *P*\<0.05, \*\*: *P*\<0.01, \*\*\*: *P*\<0.001. For clarity, only significant differences with vehicle-treated cultures are shown.](1031359.fig1){#f1-1031359}

OTSSP167 inhibits bone matrix resorption
----------------------------------------

Bone matrix resorption decreased following OTSSP167 treatment of both primary human ([Figure 2A](#f2-1031359){ref-type="fig"} and [2C](#f2-1031359){ref-type="fig"}) and murine ([Figure 2B](#f2-1031359){ref-type="fig"} and [2D](#f2-1031359){ref-type="fig"}) osteoclast cultures. Of note, this effect was apparent in human osteoclasts treated with 10 nM OTSSP167, suggesting that the enlarged osteoclasts that are present at this concentration are not efficiently resorbing matrix. Similarly, murine osteoclast bone resorption was inhibited at 1 nM OTSSP167, a concentration at which no effect on osteoclast differentiation was observed. The blocking effect of OTSSP167 on osteoclast differentiation was confirmed at mRNA level, where we observed an increased expression of the negative regulator IRF8 and decreased expression of *NFATC1* and *DCSTAMP* ([Figure 2E](#f2-1031359){ref-type="fig"}). On the other hand, we detected an increase in *EZH2* mRNA and protein levels, while the phosphorylation level of *FOXM1* decreased (*Online Supplementary Figure S1B*). Finally, we observed no difference in actin ring formation in mature osteoclasts following OTSSP167 treatment ([Figure 2F](#f2-1031359){ref-type="fig"}).

![OTSSP167 inhibits bone matrix resorption. A+B) Representative images of Von Kossa-stained bone matrix resorption assays of huOC and RAW264.7-derived osteoclast cultures continuously treated with a range of OTSSP167 concentrations. C+D) Quantification of the matrix resorption area in huOC and RAW264.7-derived osteoclast cultures. E) Real-time PCR analysis of *MELK, IRF8, DC-STAMP* and *NFATc1* following OTSSP167 treatment of RAW264.7-derived osteoclast cultures. F) Representative confocal microscopy images of phalloidin-FITC-stained RAW264.7-derived osteoclast cultures. All data are represented as mean +/− standard error. \*: *P*\<0.05, \*\*: *P*\<0.01, \*\*\*: *P*\<0.001. For clarity, only significant differences with vehicle-treated cultures are shown.](1031359.fig2){#f2-1031359}

Established osteoclast cultures are sensitive to OTSSP167
---------------------------------------------------------

In order to confirm that the effects of OTSSP167 on osteoclast function are not solely due to a decrease in monocyte viability, we initiated treatment of mature RAW264.7 osteoclasts after the final day of differentiation (day 5). In this setting, treatment with up to 10 nM OTSSP167 had no effect on the number of osteoclasts ([Figure 3A](#f3-1031359){ref-type="fig"} and [3C](#f3-1031359){ref-type="fig"}). Initiation of OTSSP167 treatment on day 5 or day 7 of *in vitro* matrix resorption assays markedly reduced bone matrix resorption ([Figure 3B](#f3-1031359){ref-type="fig"} and [3D](#f3-1031359){ref-type="fig"}). Mature osteoclasts appeared at day 5 in these cultures and the presence of mature osteoclasts at the end of both DMSO- and OTSSP167-treated cultures was confirmed (*not shown*). Twenty-four hour treatment of mature osteoclasts had no impact on *NFATc1* or *TRAP* mRNA levels ([Figure 3E](#f3-1031359){ref-type="fig"}). However, we found OTSSP167 greatly reduced *CTSK* expression and greatly increased calcitonin receptor (*CALCR*) expression by mature osteoclasts ([Figure 3E](#f3-1031359){ref-type="fig"}). Finally, as multiple reports indicate that both osteoclast differentiation and bone resorption by osteoclasts depend on the generation of reactive oxygen species (ROS),^[@b23-1031359],[@b24-1031359]^ we assessed whether OTSSP167 could hamper the generation of ROS by mature osteoclasts and this was indeed the case ([Figure 3F](#f3-1031359){ref-type="fig"}).

![Established osteoclast cultures are sensitive to OTSSP167. A) Representative images of TRAP-stained RAW264.7-derived osteoclast cultures treated with a range of OTSSP167 concentrations. Treatment of these cultures was initiated after the final day of osteoclast differentiation (day 5). B) Representative images of Von Kossa-stained bone matrix resorption assays of huOC and RAW264.7-derived osteoclast cultures treated with a range of OTSSP167 concentrations. Treatment of these cultures was initiated when mature osteoclasts appeared (early: day 5, late: day 7). C) Quantification of osteoclast numbers per field of view (N.OC/FOV) in RAW264.7-derived cultures treated with OTSSP167 starting at day 5. D) Quantification of the matrix resorption area in RAW264.7-derived osteoclast cultures treated with OTSSP167 starting at day 5 or day 7. E) Real-time PCR analysis of osteoclast differentiation markers following OTSSP167 treatment starting at day 5 of RAW264.7-derived osteoclast cultures. F) ROS generation by RAW264.7-derived osteoclasts treated with OTSSP167 starting on day 5. All data are represented as mean +/− standard error. \*: *P*\<0.05, \*\*: *P*\<0.01, \*\*\*: *P*\<0.001.](1031359.fig3){#f3-1031359}

OTSSP167 stimulates osteoblast function
---------------------------------------

Contrary to osteoclasts, *MELK, EZH2* and *FOXM1* expression decreased during OB formation indicating an inhibitory role in OB development ([Figure 4A](#f4-1031359){ref-type="fig"}). These data suggest an opposing role for these molecules in OB formation which is in line with the results obtained with OTSSP167. Treatment of BMSC-TERT with OTSSP167 for 24 hours resulted in decreased *MELK, EZH2* and *FOXM1* protein levels ([Figure 4B](#f4-1031359){ref-type="fig"}). Although monocyte viability was considerably reduced following OTSSP167 treatment in the low nanomolar range, bone marrow stromal cell viability was unaffected at these concentrations (IC50: 800.2 nM) ([Figure 4C](#f4-1031359){ref-type="fig"}). Accordingly, no G2/M cell cycle arrest was detected (*Online Supplementary Figure S1A*). Functionally, OTSSP167 increased collagen deposition by osteoblasts ([Figure 4D](#f4-1031359){ref-type="fig"} and [4E](#f4-1031359){ref-type="fig"}) and induced a marked increase in matrix mineralization ([Figure 4D](#f4-1031359){ref-type="fig"} and [4F](#f4-1031359){ref-type="fig"}). Finally, we determined the effect of OTSSP167 on osteoblast marker gene expression and found that osterix (*OSX*) expression was increased. Conversely *RUNX2*, osteopontin (*OPN*) and interleukin-6 (*IL-6*) expression were decreased ([Figure 4G](#f4-1031359){ref-type="fig"}).

![OTSSP167 stimulates osteoblast function. A) *MELK, EZH2* and *FOXM1* mRNA levels during osteoblast differentiation of BMSC-TERT cells. B) The effect of OTSSP167 treatment on *MELK, EZH2* and *FOXM1* protein levels in BMSC-TERT osteoblast cultures. C) MTT assay on BMSC-TERT cells incubated with a range of OTSSP167 concentrations. D) Representative images of sirius red (top panels) and alizarin red (bottom panels) stainings of BMSC-TERT osteoblast cultures treated with a range of OTSSP167 concentrations. E) Quantification of collagen deposition by BMSC-TERT osteoblasts following OTSSP167 treatment. F) Quantification of matrix mineralization by BMSC-TERT osteoblasts following OTSSP167 treatment. G) Real-time PCR analysis of osteoblast differentiation marker expression by BMSC-TERT osteoblasts following OTSSP167 treatment. All data are represented as mean +/− standard error. \*:*P*\<0.05, \*\*:*P*\<0.01, \*\*\*:*P*\<0.001. Except for panel A, only significant differences with vehicle-treated cultures are shown for clarity.](1031359.fig4){#f4-1031359}

Preclinical activity of OTSSP167 in multiple myeloma bone disease
-----------------------------------------------------------------

Our *in vitro* data indicate that OTSSP167 blocks osteoclast activity while stimulating osteoblast activity. Therefore, we assessed the potential of OTSSP167 as a novel therapy for MMBD *in vivo* in the 5TGM.1 MM model. The effects of OTSSP167 on myeloma development are given and discussed in detail in a separate publication.^[@b7-1031359]^ OTSSP167 treatment prevented the development of MMBD and this effect was similar at all dosing schedules tested ([Figure 5A](#f5-1031359){ref-type="fig"}). OTSSP167 reduced the number of cortical perforations in MM-bearing mice ([Figure 5B](#f5-1031359){ref-type="fig"}), without affecting cortical thickness (Ct.Th) (*Online Supplementary Figure S1E*). The loss of trabecular bone volume (Tb.BV/TV) that occurs in MM-bearing mice compared to healthy controls was completely prevented following treatment with OTSSP167 ([Figure 5C](#f5-1031359){ref-type="fig"}). This was due to an increase in the number of trabeculae (Tb.N) ([Figure 5D](#f5-1031359){ref-type="fig"}) and a decrease in trabecular separation (Tb.Sp) (*Online Supplementary Figure S1F*). As a result, trabecular connectivity density (Conn.Dn) was similar to healthy mice in OTSSP167-treated MM-bearing mice (*Online Supplementary Figure S1G*). Trabecular thickness was not affected in MM-bearing mice (*Online Supplementary Figure S1H*). Importantly, the observed prevention of MMBD in these mice does not appear to be solely due to a decreased tumor load following OTSSP167 treatment, as MMBD was prevented at a dose (7.5 mg/kg/2d) which had no effect on tumor load ([Figure 5E](#f5-1031359){ref-type="fig"}).

![Preclinical activity of OTSSP167 in multiple myeloma bone disease. A) Representative 3D-reconstructions of distal femurs of naive or 5TGM.1 MM-bearing mice treated with vehicle solution or various dosing schedules of OTSSP167. Upper panels show a frontal view. Lower panels show a frontal section of the frontal view. Cortical bone is colored white, trabecular bone is colored green. B) Quantification of the number of cortical perforations with a diameter of at least 50 μm. CTAn analysis was performed and C) trabecular bone volume (Tb.BV/TV), D) trabecular number (Tb.N), E) Superimposition of tumor load data (red line, relative to vehicle-treated MM-bearing mice) and Tb.BV/TV (black bars, relative to naive mice) in the different mouse cohorts. All data are represented as mean +/− standard error. All statistical differences are reported *versus* vehicle-treated mice. No difference between the different dosing schedules was observed. \*:*P*\<0.05, \*\*:*P*\<0.01, \*\*\*:*P*\<0.001.](1031359.fig5){#f5-1031359}

OTSSP167 decreases osteoclast activity and restores osteoblast activity in multiple myeloma-bearing mice
--------------------------------------------------------------------------------------------------------

Because of the lack of an anti-myeloma effect with an OTSSP167 dose of 7.5 mg/kg/2d, we performed immunohistomorphometry on the bones of mice from this cohort. The increase in osteoclast surface observed in MM-bearing mice was completely prevented after OTSSP167 treatment ([Figure 6A](#f6-1031359){ref-type="fig"} and [6D](#f6-1031359){ref-type="fig"}). Together with an increase in osteoclast activity, osteoblast surface was suppressed in MM-bearing mice and OTSSP167 restored osteoblast surface levels to those observed in naive mice ([Figure 6B](#f6-1031359){ref-type="fig"} and [6E](#f6-1031359){ref-type="fig"}). Finally, given the effect of OTSSP167 on osteoblast collagen deposition and mineralizing activity *in vitro*, we analyzed osteoid and found that OTSSP167 increased osteoid surface in MM-bearing mice ([Figure 6C](#f6-1031359){ref-type="fig"} and [6F](#f6-1031359){ref-type="fig"}). In addition, osteoid thickness was reduced in OTSSP167-treated MM-bearing mice ([Figure 6G](#f6-1031359){ref-type="fig"}).

![OTSSP167 decreases osteoclast activity and restores osteoblast activity in multiple myeloma-bearing mice. A) Representative images of TRAP-stained distal femur sections of naive, vehicle- and OTSSP167-treated mice from the 7.5 mg/kg/2d cohort, which showed no effect on MM tumor load. 40× amplifications are shown in the inserts. B) Representative images of toluidine blue-stained distal femur sections from the same cohort. C) Representative images of Masson's trichrome stained distal femur sections from the same cohort. D) Quantification of osteoclast surface (Oc.S/BS). E) Quantification of osteoblast surface (Ob.S/BS). F) Quantification of osteoid surface (OS/BS). G) Quantification of osteoid thickness (O.Th). All data are represented as mean +/− standard error. \*:*P*\<0.05, \*\*:*P*\<0.01, \*\*\*:*P*\<0.001.](1031359.fig6){#f6-1031359}

Discussion
==========

In this preclinical study, we demonstrated that MELK inhibitor OTSSP167 is a promising novel therapeutic agent for MMBD since OTSSP167 treatment blocked osteoclast activity and stimulated osteoblast activity in vitro, and completely prevented the development of MMBD in MM-bearing mice.

Consistent with an osteoclast stimulating activity of factors downstream of MELK, *MELK* mRNA levels increased during osteoclastogenesis. In addition, we found significant mRNA changes in *EZH2* and the negative regulator *IRF8* known to influence the crucial differentiation factor *NFATC1* which was found to be upregulated during osteoclast differentiation (illustrated in *Online Supplementary Figure S1C*). OTSSP167 decreased MELK protein levels in RAW264.7 cells, which agrees with previous studies on various cell types.^[@b25-1031359],[@b26-1031359]^ Of note, OTSSP167 can have off-target effects, which could partially account for the effects of OTSSP167 on osteoclast and osteoblast function.^[@b27-1031359],[@b28-1031359]^ In accordance with previous reports implicating MELK in G2/M transition and proliferation, OTSSP167 decreased the viability of monocytes due to G2/M cell cycle arrest.^[@b26-1031359],[@b27-1031359],[@b29-1031359],[@b30-1031359]^ The decreased progenitor cell viability resulted in a decreased osteoclast differentiation following OTSSP167 treatment. It is difficult to differentiate between an anti-proliferative effect on progenitor cells and an anti-osteoclast differentiation effect. We observed that 2 pathways, known to interact with MELK, were affected by OTSSP167: i) the transcriptional factor FOXM1 which is implicated in proliferation and ii) the EZH2-IRF8-NFATC1 axis, involved in osteoclast differentiation. Unexpectedly, EZH2 levels increased, which can be explained by the strong link between cell cycle arrest and CDK1/2-dependent EZH2 phosphorylation on different residues (T487), which can either disrupt the binding of EZH2 to other partners of the polycomb repressive complex^[@b31-1031359]^ or target it for ubiquitin-mediated degradation.^[@b32-1031359]^ EZH2 thus becomes less functional, which results is a decline in H3K27 trimethylation and a de-repression of EZH2 target genes (in our case *IRF8*).^[@b33-1031359]^ When mature osteoclasts were treated with OTSSP167, their numbers remained unaltered but matrix resorption was drastically decreased, further corroborating that OTSSP167 has a direct effect on osteoclast activity. Together, our data indicate that OTSSP167 inhibits osteoclast function by hampering monocytic progenitor viability as well as by directly inhibiting mature osteoclast function.

*MELK, EZH2* and *FOXM1* mRNA levels decreased during osteoblast differentiation, consistent with an inhibitory role of MELK and downstream factors such as EZH2 on osteoblast function.^[@b16-1031359],[@b17-1031359]^ Contrary to osteoclasts and various malignant cells, BMSC-TERT viability was not affected following OTSSP167 treatment at similar concentrations. OTSSP167 treatment increased collagen deposition and strongly stimulated mineralization activity of osteoblasts *in vitro* and this coincided with an increase in *OSX* levels but a decrease in *RUNX2, OPN* and *IL-6* mRNA levels. The pro-mineralization activity of OTSSP167 is likely mediated by EZH2 as treatment with an EZH2 inhibitor showed a similar effect.^[@b16-1031359]^ However, the decrease in *RUNX2* expression following OTSSP167 treatment does not correspond with the described role of EZH2 as a suppressor of RUNX2 transcription.^[@b16-1031359]^ Alternative mechanisms of OTSSP167-induced osteoblast maturation include a marked decrease in the expression of OPN, a non-collagenous bone matrix protein that inhibits matrix mineralization^[@b34-1031359]^ and IL-6,^[@b34-1031359]^ a potent growth factor for MM cells, but also a negative regulator of osteoblast differentiation^[@b35-1031359]^ and inducer of bone resorption.^[@b36-1031359]^ Deregulation of these genes in conjunction with the above-mentioned upregulation of *OSX*, a master regulator of mineralization, likely mediates the pro-osteogenic activity of OTSSP167.

The regulation of MELK expression and activity by upstream signaling pathways remains poorly understood including in bone cells. E2F1^[@b37-1031359]^ and FOXM1^[@b10-1031359]^ have been shown to regulate *MELK* gene transcription, the former in osteoblastic MC3T3-E1 cells. Of note, E2F1 has been implicated in increased osteoclastogenesis and osteoblast activity.^[@b38-1031359],[@b39-1031359]^ MELK both regulates and is regulated by one family of MAP kinases, the c-Jun NH(2)-terminal kinases (JNK2), that acts downstream of the RANK-receptor.^[@b40-1031359]^ Interestingly, JNK2 does not seem to be required for osteoclast differentiation, but rather appears to be involved in osteoclast survival.^[@b41-1031359]^

Given the promising *in vitro* data, we assessed whether OTSSP167 would affect the development of MMBD in the murine 5TGM.1 MM model. Although this model reflects human myeloma and associated bone disease in an immunocompetent setting, it should be noted that MM growth in this model progresses rapidly. This cell line allows *in vivo* studies, however, it also shows a BM-independent growth *in vitro* and its murine origin may not reflect all the human aspects of myeloma disease (from cytogenetic and molecular point of view). We have previously shown that the dosing schemes we used dose-dependently decreased MM tumor load.^[@b7-1031359]^ OTSSP167 completely prevented the development of MMBD at all doses, with no difference between the treatment groups. Both the development of lytic cortical lesions and the large loss of trabecular bone were completely prevented in MM-bearing mice treated with OTSSP167. Importantly, this effect also occurred at an OTSSP167 concentration which had no effect on MM tumor load (7.5 mg/kg/2d), indicating that OTSSP167 has a direct effect on bone cells and does not solely reduce MMBD by reducing MM tumor load. In fact, given the lower concentration of OTSSP167 needed to achieve an anti-MMBD effect, our data suggest that OTSSP167 could exert its anti-MM effect in part by normalizing bone homeostasis. Indeed, the reduced osteoclast numbers following OTSSP167 treatment likely result in reduced myeloma pro-survival factor levels and increased myeloma anti-proliferative factor levels, respectively. Upon treatment with OTSSP167, we found decreased mRNA expression levels of insulin-like growth factor 1 (IGF-1), osteopontin, a proliferation-inducing ligand (APRIL) and interleukin-10 (IL-10) (*Online Supplementary Figure S1D*).

In conclusion, this study provides a novel approach for the treatment of MMBD. The maintenance of bone anabolic activity by OTSSP167 is promising and warrants further investigation. Reducing MM patient morbidity and mortality via the combined anti-MM and anti-MMBD effect of OTSSP167 holds great clinical promise and our results warrant similar studies in other cancers with bone involvement.
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